BeyondSpring Inc.

BeyondSpring Inc. is a biopharmaceutical company, not a family office. The firm's primary focus is on developing cancer treatments, including its lead asset,...

BeyondSpring Inc.

BeyondSpring Inc. is a biopharmaceutical company, not a family office. The firm's primary focus is on developing cancer treatments, including its lead asset, plinabulin, a novel small molecule compound. The firm has not publicly disclosed financial details such as AUM or deployment figures. Its operations are focused on drug development rather than investment management. No team size, offices, or recent activity beyond public filings were available in the provided sources. The firm's structure as a public company differs from that of a family office, with no disclosed family wealth origin.

General information

Firm type

other

Who runs investment decisions at BeyondSpring Inc.?

BeyondSpring Inc. is a publicly traded biopharmaceutical company, not a family office. Investment decisions are made by its board of directors and management team, led by CEO Dr. Lan Huang. The firm focuses on drug development rather than capital allocation.

How does BeyondSpring Inc. source proprietary deal flow?

BeyondSpring Inc. is a clinical-stage drug developer, not an investment firm. It does not source deal flow; it develops its own drug candidates, primarily plinabulin, for cancer treatment. Its strategy involves in-house research and clinical trials.

What investment stages does BeyondSpring Inc. typically target?

BeyondSpring Inc. does not target investment stages. It is a clinical-stage biotechnology company focused on developing therapies through phases of clinical trials. Its capital is allocated to drug research, clinical trials, and regulatory activities.

Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: Aug 11, 2026. Continuous refresh with full update cycles at least every 30 days.